KRAS A146T
|
HCC
|
KRAS A146T
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS A146T
|
CRC
|
KRAS A146T
|
CRC
|
trametinib + palbociclib Sensitive: D – Preclinical
|
trametinib + palbociclib Sensitive: D – Preclinical
|
KRAS A146T
|
CRC
|
KRAS A146T
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|